A DIRECTOR of a top Oxford drugs company has been suspended after allegations of breaches in secrecy.

The suspension of Dr Andrew Millar, director of clinical research at British Biotech, wiped £100m off the value of the firm's shares.

The company is developing two blockbuster drugs for the treatment of cancer and pancreatitis.

Dr Millar, 42, was suspended as a full investigation was launched to establish whether any British Biotech secrets have been divulged.

A company spokesman said: "An investigation has been ordered into alleged breaches of company rules on confidentiality.

"It is an offence for any employee to discuss confidential affairs of the company with external parties."

The firm said no financial impropriety or personal indiscretion was involved and that the company's crucial drugs trials would be unaffected.

British Biotech, based in Watlington Road, Cowley, invests millions of pounds every year in drugs research.

The company, founded 11 years ago, has continually recorded huge losses.

But hopes of new drugs being developed have made the firm a favourite with stock market investors.

The main hopes are on Marimastat, an oral anti-cancer drug being tested on six types of tumour including lung, stomach, and certain brain cancers.

It is also pressing ahead with clinical trials on Zacutex, used for the treatment of acute pancreatitis.

Converted for the new archive on 30 June 2000. Some images and formatting may have been lost in the conversion.